Why GeneDX Stock Surged Higher This Week

Shares in genetic testing company GeneDx Holdings (NASDAQ: WGS) continued their wild ride in 2025 and are up almost 34% on the week to Friday morning. This week's move follows the American Academy of Pediatrics' (AAP) updated guidance, which recommends exome and genetic testing as a first-line test for children with global developmental delays (GDDs) and intellectual disabilities (IDs).

That's good news for GeneDx because it has these tests. Additionally, it could encourage the increased adoption of genetic testing to identify rare diseases for which GeneDx has a large dataset.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

What does the report recommend?

Digging into the details of the updated guidance, the report states that "Pursuing genetic diagnosis for GDD/ID allows for accurate prognostication, facilitates surveillance for potential disorder-related complications, provides accurate recurrence risk in families interested in having additional children, and allows for prenatal diagnostic testing and preimplantation genetic diagnosis (PGD)."

Image source: Getty Images.

The report cites research stating that the global prevalence of GDD/ID is 1% to 3%. As such, action taken in response to the updated guidance could move the needle for GeneDx, and it encouraged Jefferies to raise its price target on the stock to $105 from $80.

What it means to investors

The update is good news, but GeneDx remains a speculative investment. There's little doubt that genetic testing has a bright future, but the company faces significant competition in this field. Its principal value lies in its rare disease datasets and analytical capability, but that could arguably get more competitive if rivals with deeper pockets move into the rare disease market and chip away at GeneDx's business moat.

Should you invest $1,000 in GeneDx right now?

Before you buy stock in GeneDx, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GeneDx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $945,846!*

Now, it’s worth noting Stock Advisor’s total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of June 23, 2025

Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Jefferies Financial Group. The Motley Fool has a disclosure policy.